{"id":949697,"date":"2026-04-07T21:38:25","date_gmt":"2026-04-08T01:38:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/"},"modified":"2026-04-07T21:38:25","modified_gmt":"2026-04-08T01:38:25","slug":"corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/","title":{"rendered":"Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC"},"content":{"rendered":"
\n

NEW YORK CITY and NEW ORLEANS, April 07, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti<\/a>, LLC (\u201cKSF\u201d) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026<\/u><\/strong> to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics<\/a> Incorporated (NasdaqCM: CORT) (\u201cCorcept\u201d or the \u201cCompany\u201d), if they purchased or otherwise acquired the Company\u2019s shares between October 31, 2024 and December 30, 2025, inclusive (the \u201cClass Period\u201d). This action is pending in the United States District Court for the Northern District of California.<\/p>\n

\n What You May Do<\/strong>\n <\/p>\n

If you purchased shares of Corcept and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https:\/\/www.ksfcounsel.com\/cases\/nasdaqcm-cort\/<\/a> to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 21, 2026<\/u><\/strong>.<\/p>\n

\n About the Lawsuit<\/strong>\n <\/p>\n

Corcept and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.\u00a0\u00a0<\/p>\n

The complaint alleges that, during the Class Period, the Company represented to investors that there was a high likelihood that one of its lead new product candidates, relacorilant, would receive approval from the U.S. Food and Drug Administration (\u201cFDA\u201d) after the Company\u2019s New Drug Application (\u201cNDA\u201d) submission. However, on December 31, 2025, the Company disclosed that the FDA had issued a Complete Response Letter (\u201cCRL\u201d) regarding the NDA for relacorilant and that it had \u201cconcluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.\u201d<\/p>\n

On this news, the price of Corcept\u2019s shares plummeted by $35.40 per share, or 50.4%, from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025.<\/p>\n

The case is Allegheny County Employees\u2019 Retirement System v. Corcept Therapeutics Incorporated, <\/em>No. 26-cv-01525.<\/p>\n

About Kahn Swick & Foti<\/a>, LLC<\/p>\n

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.<\/p>\n

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services<\/p>\n

To learn more about KSF, you may visit www.ksfcounsel.com<\/a>.<\/p>\n

Contact:<\/p>\n

Kahn Swick & Foti, LLC<\/p>\n

Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com<\/a>
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163<\/p>\n

CONNECT WITH US: Facebook<\/a> || Instagram<\/a> || YouTube<\/a> || TikTok<\/a> || LinkedIn<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK CITY and NEW ORLEANS, April 07, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (\u201cKSF\u201d) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (\u201cCorcept\u201d or the \u201cCompany\u201d), if they purchased or otherwise acquired the Company\u2019s shares between October 31, 2024 and December 30, 2025, inclusive (the \u201cClass Period\u201d). This action is pending in the United States District Court for the Northern District of California. What You May Do If you purchased shares of Corcept and would like to discuss your legal rights and how … <\/p>\n

Continue reading “Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949697","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCorcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK CITY and NEW ORLEANS, April 07, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (\u201cKSF\u201d) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (\u201cCorcept\u201d or the \u201cCompany\u201d), if they purchased or otherwise acquired the Company\u2019s shares between October 31, 2024 and December 30, 2025, inclusive (the \u201cClass Period\u201d). This action is pending in the United States District Court for the Northern District of California. What You May Do If you purchased shares of Corcept and would like to discuss your legal rights and how … Continue reading "Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T01:38:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTg5OSM3NTI0NTk5IzIwMTc2NzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC\",\"datePublished\":\"2026-04-08T01:38:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\\\/\"},\"wordCount\":521,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTg5OSM3NTI0NTk5IzIwMTc2NzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\\\/\",\"name\":\"Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTg5OSM3NTI0NTk5IzIwMTc2NzE=\",\"datePublished\":\"2026-04-08T01:38:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTg5OSM3NTI0NTk5IzIwMTc2NzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTg5OSM3NTI0NTk5IzIwMTc2NzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/","og_locale":"en_US","og_type":"article","og_title":"Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - Market Newsdesk","og_description":"NEW YORK CITY and NEW ORLEANS, April 07, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (\u201cKSF\u201d) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (\u201cCorcept\u201d or the \u201cCompany\u201d), if they purchased or otherwise acquired the Company\u2019s shares between October 31, 2024 and December 30, 2025, inclusive (the \u201cClass Period\u201d). This action is pending in the United States District Court for the Northern District of California. What You May Do If you purchased shares of Corcept and would like to discuss your legal rights and how … Continue reading \"Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-08T01:38:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTg5OSM3NTI0NTk5IzIwMTc2NzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC","datePublished":"2026-04-08T01:38:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/"},"wordCount":521,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTg5OSM3NTI0NTk5IzIwMTc2NzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/","name":"Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTg5OSM3NTI0NTk5IzIwMTc2NzE=","datePublished":"2026-04-08T01:38:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTg5OSM3NTI0NTk5IzIwMTc2NzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTg5OSM3NTI0NTk5IzIwMTc2NzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corcept-therapeutics-incorporated-securities-fraud-class-action-result-of-fda-approval-issues-and-50-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-foti-llc-6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949697"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949697\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}